Literature DB >> 8640683

Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studies.

Y Harabuchi1, S Imai, J Wakashima, M Hirao, A Kataura, T Osato, S Kon.   

Abstract

BACKGROUND: The authors have previously demonstrated nasal T-cell lymphoma (NTL) associated with Epstein-Barr virus (EBV). The detailed clinical, phenotypic, and genotypic features and the role of EBV in lymphomagenesis remain to be clarified.
METHODS: The study group consisted of 18 patients with NTL. The phenotype was determined by immunoperoxidase staining with various monoclonal antibodies. Genotypic study was done using Southern blot hybridization. The presence of EBV-encoded small nuclear early region (EBER) RNA and EBV DNA were determined by in situ hybridization. The expression of EBV-encoded nuclear antigen (EBNA) and latent membrane protein (LMP1) were identified by immunohistologic methods. Clonotypic analysis of EBV genomes was performed by Southern blot hybridization with EBV termini fragment probe.
RESULTS: The clinical features of NTL were characterized as prolonged fever (16 patients), widespread dissemination into distant sites (13 patients), and poor prognosis with a median survival of only 6 months. EBER transcripts were identified in 16 of 18 patients. Monoclonal EBV genomes EBNA1 and LMP1 were also detected in all EBER-positive cases tested. All 18 patients expressed pan-T antigens such as MT1, CD45RO, and/or CD2. The rearrangements of T-cell receptor (TCR)-beta, -gamma, and/or -delta genes were shown in all 11 patients tested. The natural killer (NK) cell phenotype CD56 was expressed in all EBV-positive cases tested, and was not detected in EBV-negative cases. Seven EBV-positive cases expressed a TCR-delta chain with rearranged TCR-gamma or -delta genes whereas both EBV-negative cases corresponded to alpha beta T-cell lymphoma, which expressed a TCR-beta chain with a rearranged TCR-beta gene.
CONCLUSIONS: These data suggest that EBV-positive NTL may be derived from the lineage of NK-like T-cells or gamma delta T-cells, and that EBV may play a role in lymphomagenesis. Therefore, we propose that NTL which has peculiar clinical and histologic features could be classified as a new lymphoma entity.

Entities:  

Mesh:

Year:  1996        PMID: 8640683     DOI: 10.1002/(SICI)1097-0142(19960515)77:10<2137::AID-CNCR27>3.0.CO;2-V

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

1.  Contradictory Concepts in the Etiology and Regression of Kaposi's Sarcoma. The Ferenc Györkey Memorial Lecture.

Authors:  Joseph G Sinkovics
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

2.  Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma.

Authors:  Masayoshi Nagamine; Miki Takahara; Kan Kishibe; Toshihiro Nagato; Hideyuki Ishii; Nobuyuki Bandoh; Takeshi Ogino; Yasuaki Harabuchi
Journal:  Virus Genes       Date:  2006-08-18       Impact factor: 2.332

3.  CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.

Authors:  Liang Wang; Zhao Wang; Zhong-Jun Xia; Yue Lu; Hui-Qiang Huang; Yu-Jing Zhang
Journal:  Tumour Biol       Date:  2015-05-03

4.  Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.

Authors:  Hui-Hui Ma; Li-Ting Qian; Hai-Feng Pan; Lin Yang; Hong-Yan Zhang; Zhi-Hua Wang; Jun Ma; Yu-Fei Zhao; Jin Gao; Ai-Dong Wu
Journal:  Med Oncol       Date:  2009-08-15       Impact factor: 3.064

5.  Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.

Authors:  Ningjing Lin; Wenjing Ku; Yuqin Song; Jun Zhu; Zheming Lu
Journal:  Oncologist       Date:  2019-04-02

6.  Nasal natural killer/T-cell lymphoma and its association with type "i"/XhoI loss strain Epstein-Barr virus in Chile.

Authors:  M E Cabrera; Y Eizuru; T Itoh; C Koriyama; Y Tashiro; S Ding; S Rey; S Akiba; A Corvalan
Journal:  J Clin Pathol       Date:  2006-06-14       Impact factor: 3.411

7.  c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma.

Authors:  Takumi Kumai; Yoshinari Matsuda; Takayuki Ohkuri; Kensuke Oikawa; Kei Ishibashi; Naoko Aoki; Shoji Kimura; Yasuaki Harabuchi; Esteban Celis; Hiroya Kobayashi
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

8.  Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection.

Authors:  Michiko K Oyoshi; Hiroshi Nagata; Nobuhiro Kimura; Yu Zhang; Ayako Demachi; Toshiro Hara; Hirokazu Kanegane; Yoshinobu Matsuo; Tomohiro Yamaguchi; Tomohiro Morio; Atsuyoshi Hirano; Norio Shimizu; Kohtaro Yamamoto
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

9.  Primary laryngeal T/NK-cell lymphoma, nasal-type: an unusual location for an aggressive subtype of extranodal lymphoma.

Authors:  Juan C Tardío; Amalia Moreno; Cecilia Pérez; José Angel Hernández-Rivas; Montserrat López-Carreira
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06       Impact factor: 2.503

10.  CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.

Authors:  Takumi Kumai; Toshihiro Nagato; Hiroya Kobayashi; Yuki Komabayashi; Seigo Ueda; Kan Kishibe; Takayuki Ohkuri; Miki Takahara; Esteban Celis; Yasuaki Harabuchi
Journal:  Cancer Immunol Immunother       Date:  2015-03-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.